Details of the Drug Reposition

General Information of This Drug (ID: DMVLXMG)

Drug Name
Camostat mesylate   DMVLXMG
Synonyms
Camostat (mesylate); Camostat Methanesulfonate; Camostat methanesulfate; DSSTox_CID_238; DSSTox_GSID_20238; DSSTox_RID_75452; FOY 305; FOY-305; FOY305; Foipan; Foipan (TN); Foipan mesylate; NCGC00167526-01; Q-200778; UNII-451M50A1EQ; camostat mesilate; 451M50A1EQ; C21H26N4O8S; CAS-59721-29-8; CHEMBL85164
Therapeutic Class
Antiviral Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 2 [1]
------------------------------------------------------------------------------------
2 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Middle East Respiratory Syndrome (MERS) DIS5VPYU 1D64 Investigative [2]
Severe acute respiratory syndrome (SARS) DISYW14W 1D65 Investigative [2]
------------------------------------------------------------------------------------

References

1 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8.
2 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.